Skip to main content.

Annie E. Wishna, M.D.

Anne Wishna portrait
Clinical Associate Professor, Ophthalmology

Director, Residency Program, Ophthalmology

Professional Background

Dr. Wishna received her BA in College of Arts andamp; Sciences from the University of Pennsylvania and her MD from Washington University School of Medicine in St. Louis, MO. She completed her internship at Weiss Memorial Hospital at the University of Chicago and her ophthalmology residency at the New York Eye and Ear Infirmary. She was also a Clinical Instructor at the New York Eye and Ear Infirmary before entering into private practice, first at the Eye Institute of New York and then at Grin Eye Care in Olathe. She joined KU Eye/Department of Ophthalmology at the University of Kansas in December 2017 where she is currently a Clinical Assistant Professor. She also became Director of our Residency Program in January 2021. She has been selected for inclusion in Castle Connolly and 435 Magazine Top Doctors and Exceptional Women in Medicine. She received the Hadassah Health Professional Award in appreciation for outstanding service and dedication to enhancing the health of the community, through compassionate care and expertise in her area of healthcare.
Dr. Wishna sees diagnosing and treating eye disease and performing vision-saving surgeries as the most critical part of her job but believes the best part of patient care is making a personal connection. By really getting to know her patients, she is able to tailor their care to best meet their specific needs.
Her surgical focus is cataract surgery and she also perform laser procedures for glaucoma. Residents are often with her in surgery and she is a skilled and effective educator. Patients are sent to KUMC from across the state for ophthalmic trauma emergencies.


Education and Training
  • BA, College of Arts & Sciences, University of Pennsylvania , Philidelphia, PA
  • MD, Ophthalmology, Washington University School of Medicine, St. Louis, MO
  • Internship, Transitional Year, Weiss Memorial Hospital - University of Chicago, Chicago, IL
  • Residency, Ophthalmology, New York Eye and Ear Infirmary, New York, NY
Licensure, Accreditations & Certifications
  • American Board of Ophthalmology
  • DEA, Drug Enforcement Agency
  • MBRHA, Missouri Board of Registration for the Healing Arts
  • MBRHA, Missouri Board of Registration for the Healing Arts
  • MD, Arizona Medical Board
Professional Affiliations
  • Alpha Omega Alpha Honor Medical Society, Member, 2021 - Present
  • Association of University Professors of Ophthalmology, Director, 2021 - Present
  • Kansas Medical Society, Member, 2020 - Present
  • Kansas Society of Eye Physicians and Surgeons, Legislative Working Group, Member, 2020 - 2021
  • American Academy of Ophthalmology, AAO Council, Member, 2019 - 2021
  • Association of University Professors of Ophthalmology, Ad-Hoc Member, 2019 - 2021
  • Kansas City Society of Ophthalmology and Otolaryngology, Co-Chair, 2018 - 2019

Research

Overview

Since making the jump from private practice to academic medicine in late 2017, Dr. Wishna has enjoyed exposure to many research opportunities. She completed the first ever review of gender-based disease pathology and manifestation in the field of ophthalmology. Eye Conditions in Women was published in Gender and the Genome, a journal dedicated to gender-based medicine. She has been working with the Kansas City Royals to determine how visual ability translates to major league performance. She has greatly enjoyed participating in drug trials with the cancer center, where her role is to monitor for ophthalmic side effects.

Current Research and Grants
  • A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax-TF-ADC) in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer, none
  • A Phase 2, Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Choloangiocarcinoma Including FGFR2 Translocations who Failed Previous Therapy, none
  • A Phase 3 open-label, multicenter, randomized study of ASP2215 versus salvage chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutation, none
  • A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0011359C in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications, none
  • A Randomized Phase II Trial of Myeloablative versus Non-myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma, none
  • A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression versus Ipilimuab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma, none
  • A randomized, double-blind, placebo-controlled and delayed-start study of LY3314814 in mild Alzheimer’s disease dementia, none
  • A Randomized, Open-label, Phase 2 Study of Denintuzumab Mafodotin (SGN CD19A) Plus rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy versus RICE in the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) who are Candidates for Autologous Stem Cell Transplant, none
  • A randomized, phase 2 trial of Intermittent versus continuous dosing of dabrafenib (NSC-763760) AND Trametinib (NSC-63093)in BRAFV600E/K mutant melanoma, none
  • A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplifcation (Intellance 1), none
  • A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4, none
Publications
  • Berenbom, A, Milman, T, Finger, P., T. 2008. FIT biopsy for conjunctival squamous cell carcinoma with extensive intraocular invasion.. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 246 (3), 467-9
  • Banitt, M, Berenbom, A, Shah, M, Buxton, D, Milman, T. 2008. A case of polymicrobial keratitis violating an intact lens capsule.. Cornea, 27 (9), 1057-61
  • Wishna, A, Templeton, K. 2019. Eye conditions in Women, Gender and the Genome. Gender and the Genome, 4 (1-12), 1-12. https://doi.org/10.1177/2470289720907105 |
  • Alon, U., S, Berenbom, A. 2000. Idiopathic hypercalciuria of childhood: 4- to 11-year outcome.. Pediatric nephrology (Berlin, Germany), 14 (10-11), 1011-5
  • Berenbom, A, Davila, R., M, Lin, H., S, Harbour, J., W. 2007. Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy.. Eye (London, England), 21 (9), 1198-201